An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP

Immune Thrombocytopenia Clinical Trial

— ADOPT  

Official title:

An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® (Avatrombopag) in Adult Patients With Immune Thrombocytopenia (ITP)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04943042
• Other study ID #: Sobi.Doptelet-001
• Status: Active, not recruiting
• Start date: February 22, 2022
• Est. completion date: May 2025

Study information

• Verified date: February 2024
• Source: Swedish Orphan Biovitrum
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a multi-center, observational, Phase 4 study in patients with Immune Thrombocytopenia (ITP) designed to describe the real-world effectiveness of Doptelet and assess the patterns of drug utilization to add to the knowledge base regarding the use of Doptelet in routine medical practice. Patients eligible for participation will, as part of their routine medical care, be receiving Doptelet for the treatment of ITP.

Description:

This is a multi-center, observational, Phase 4 study in patients with ITP designed to describe the real-world effectiveness of Doptelet and assess the patterns of drug utilization to add to the knowledge base regarding the use of Doptelet in routine medical practice.

Patients eligible for participation will, as part of their routine medical care, be receiving Doptelet for the treatment of ITP.

The scope of the study is to collect both retrospective and prospective data. The main part of the study will be prospective collecting data on usage, effectiveness, safety, patient- and clinician-reported outcomes and health economic parameters whereas the retrospective part will consist of collection of information on previous treatments, reason for treatment switch, healthcare resource use and, if applicable, Doptelet treatment prior to enrollment. The retrospective data collection will be based on the information available in the patient's medical records. Data will be collected for up to 12 months prior to Doptelet treatment start.

Prospective data will be collected at routine clinical visits throughout the study. Patients will be followed for 12 (+6) months and will be enrolled until their first scheduled visit after 12 months of enrollment, or until early termination, whichever occurs first.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 150
• Est. completion date: May 2025
• Est. primary completion date: May 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient is =18 years of age

2. Established and well documented ITP diagnosis

3. Patient is treated with, or at enrollment prescribed, Doptelet for ITP. Decision to initiate treatment shall be made by the treating physician and independently from the decision to include the patient in the study

4. Signed and dated informed consent provided by the patient before any study-related activities are undertaken

5. Willing and able to comply with protocol requirements

Exclusion Criteria:

1. Enrollment in a concurrent clinical interventional study, or intake of an Investigational Medicinal Product (IMP), within three months prior to inclusion in this study

2. ITP secondary to Evan's syndrome, lupus and other autoimmune diseases

3. ITP secondary to other hematological disorders and hematological malignancies

4. ITP secondary to any other malignancies

5. ITP secondary to known drug toxicity

6. ITP secondary to any other disease considered relevant by the Investigator

Related Conditions & MeSH terms

• Immune Thrombocytopenia
• ITP
• Purpura, Thrombocytopenic, Idiopathic
• Thrombocytopenia

Intervention

Drug:
• Avatrombopag
According to prescription

Locations

Country	Name	City	State
Croatia	Swedish Orphan Biovitrum Research Site 131	Zagreb
Czechia	Swedish Orphan Biovitrum Research Site 122	Brno
Czechia	Swedish Orphan Biovitrum Research Site 123	Ostrava
Czechia	Swedish Orphan Biovitrum Research Site 121	Praha
Czechia	Swedish Orphan Biovitrum Research Site 124	Praha
Czechia	Swedish Orphan Biovitrum Research Site 125	Praha
Germany	Swedish Orphan Biovitrum Research Site 108	Aschaffenburg
Germany	Swedish Orphan Biovitrum Research Site 114	Augsburg
Germany	Swedish Orphan Biovitrum Research Site 116	Augsburg
Germany	Swedish Orphan Biovitrum Research Site 103	Bad Homburg
Germany	Swedish Orphan Biovitrum Research Site 106	Berlin
Germany	Swedish Orphan Biovitrum Research Site 113	Dresden
Germany	Swedish Orphan Biovitrum Research Site 102	Frankfurt
Germany	Swedish Orphan Biovitrum Research Site 105	Frankfurt
Germany	Swedish Orphan Biovitrum Research Site 104	Hannover
Germany	Swedish Orphan Biovitrum Research Site 112	Kaiserslautern
Germany	Swedish Orphan Biovitrum Research Site 101	Kassel
Germany	Swedish Orphan Biovitrum Research Site 115	Leipzig
Germany	Swedish Orphan Biovitrum Research Site 109	Schorndorf
Germany	Swedish Orphan Biovitrum Research Site 111	Stolberg
Italy	Swedish Orphan Biovitrum Research Site 509	Bologna
Italy	Swedish Orphan Biovitrum Research Site 504	Catania
Italy	Swedish Orphan Biovitrum Research Site 502	Firenze
Italy	Swedish Orphan Biovitrum Research Site 506	Meldola
Italy	Swedish Orphan Biovitrum Research Site 511	Milan
Italy	Swedish Orphan Biovitrum Research Site 510	Milano
Italy	Swedish Orphan Biovitrum Research Site 503	Roma
Italy	Swedish Orphan Biovitrum Research Site 505	Rome
Netherlands	Swedish Orphan Biovitrum Research Site 202	Apeldoorn
Netherlands	Swedish Orphan Biovitrum Research Site 204	Arnhem
Netherlands	Swedish Orphan Biovitrum Research Site 203	Den Haag
Norway	Swedish Orphan Biovitrum Research Site 302	Bergen
Norway	Swedish Orphan Biovitrum Research Site 301	Oslo
Spain	Swedish Orphan Biovitrum Research Site 611	Barcelona
Spain	Swedish Orphan Biovitrum Research Site 609	Burgos
Spain	Swedish Orphan Biovitrum Research Site 610	Granada
Spain	Swedish Orphan Biovitrum Research Site 601	Madrid
Spain	Swedish Orphan Biovitrum Research Site 605	Madrid
Spain	Swedish Orphan Biovitrum Research Site 607	Murcia
Spain	Swedish Orphan Biovitrum Research Site 606	Oviedo
Spain	Swedish Orphan Biovitrum Research Site 608	Palma De Mallorca
Spain	Swedish Orphan Biovitrum Research Site 602	Salamanca
Spain	Swedish Orphan Biovitrum Research Site 604	Sevilla
Spain	Swedish Orphan Biovitrum Research Site 603	Vigo
Switzerland	Swedish Orphan Biovitrum Research Site 802	Basel
Switzerland	Swedish Orphan Biovitrum Research Site 801	Lausanne
United Kingdom	Swedish Orphan Biovitrum Research Site 701	Bristol
United Kingdom	Swedish Orphan Biovitrum Research Site 709	Edinburgh	Scotland
United Kingdom	Swedish Orphan Biovitrum Research Site 708	Glasgow	Scotland
United Kingdom	Swedish Orphan Biovitrum Research Site 704	Leicester
United Kingdom	Swedish Orphan Biovitrum Research Site 707	London
United Kingdom	Swedish Orphan Biovitrum Research Site 710	London
United Kingdom	Swedish Orphan Biovitrum Research Site 705	Newcastle
United Kingdom	Swedish Orphan Biovitrum Research Site 702	Nottingham
United Kingdom	Swedish Orphan Biovitrum Research Site 703	Oxford

Sponsors (1)

Lead Sponsor	Collaborator
Swedish Orphan Biovitrum

Countries where clinical trial is conducted

Croatia,  Czechia,  Germany,  Italy,  Netherlands,  Norway,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cumulative number of weeks with a platelet count =30×109/L during Doptelet treatment.	Laboratory measures of platelet count will be collected if performed according to routine clinical practice and available in the patient's medical records. All analyses of platelet counts will be based on local laboratory results. Platelet count is an accepted surrogate marker for bleeding risk. Platelet count is a standard measurement commonly used both in clinical practice and in studies in patients with ITP.; Platelet counts during rescue medication use and within 4 weeks after stopping a rescue medication or following splenectomy will not be counted in the cumulative number of weeks.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	Cumulative number of weeks with a platelet count =50×109/L during Doptelet treatment.	Laboratory measures of platelet count will be collected if performed according to routine clinical practice and available in the patient's medical records. All analyses of platelet counts will be based on local laboratory results. Platelet count is an accepted surrogate marker for bleeding risk. Platelet count is a standard measurement commonly used both in clinical practice and in studies in patients with ITP.; Platelet counts during rescue medication use and within 4 weeks after stopping a rescue medication or following splenectomy will not be counted in the cumulative number of weeks.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	Number and proportion of patients with a platelet count =30×109/L, for at least 8 consecutive weeks.	Laboratory measures of platelet count will be collected if performed according to routine clinical practice and available in the patient's medical records. All analyses of platelet counts will be based on local laboratory results.Platelet count is an accepted surrogate marker for bleeding risk. Platelet count is a standard measurement commonly used both in clinical practice and in studies in patients with ITP.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	Number and proportion of patients with a platelet count =50×109/L for at least 8 consecutive weeks.	Laboratory measures of platelet count will be collected if performed according to routine clinical practice and available in the patient's medical records. All analyses of platelet counts will be based on local laboratory results.Platelet count is an accepted surrogate marker for bleeding risk. Platelet count is a standard measurement commonly used both in clinical practice and in studies in patients with ITP.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	Number and proportion of patients experiencing WHO bleeding grade = 2.	All bleeding events will be assessed by the Investigator according to the WHO bleeding scale where the severity of the bleeding is graded from 0 to 4 (0=no bleeding; 1=petechial bleeding; 2=mild blood loss (clinically significant); 3=gross blood loss; requires transfusion (severe); 4=debilitating blood loss, retinal or cerebral associated with fatality).	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	Number and proportion of patients requiring rescue medication.	Information will be collected via the patient's medical records.	Data will be collected retrospectively via the medical records for a time period of 12 months prior to Doptelet start as well as prospectively for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	Time from Doptelet treatment start to platelet count =30×109/L.	Laboratory measures of platelet count will be collected if performed according to routine clinical practice and available in the patient's medical records. All analyses of platelet counts will be based on local laboratory results.Platelet count is an accepted surrogate marker for bleeding risk. Platelet count is a standard measurement commonly used both in clinical practice and in studies in patients with ITP.	Data will be collected retrospectively via the medical records for a time period of 12 months prior to Doptelet start as well as prospectively for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	Time from Doptelet treatment start to platelet count =50×109/L.	Laboratory measures of platelet count will be collected if performed according to routine clinical practice and available in the patient's medical records. All analyses of platelet counts will be based on local laboratory results.Platelet count is an accepted surrogate marker for bleeding risk. Platelet count is a standard measurement commonly used both in clinical practice and in studies in patients with ITP.	Data will be collected retrospectively via the medical records for a time period of 12 months prior to Doptelet start as well as prospectively for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	Doptelet dose and dosing frequency per patient (assessed by prescription).	Information will be collected via the patient's medical records.	Data will be collected retrospectively via the medical records for a time period of 12 months prior to Doptelet start as well as prospectively for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	Adherence to Doptelet treatment assessed via the 8-item Morisky Medication Adherence Scale (MMAS-8).	MMAS-8 is an 8-item structured, self-reported medication adherence measure. The self-reported measure of medication taking was developed from a previously validated 4-item scale and supplemented with additional items addressing the circumstances surrounding adherence behavior. Each item measures a specific medication-taking behavior and not a determinant of adherence behavior. Response categories are yes/no for each item with a dichotomous response and a 5-point Likert response for the last item. Adherent patients are identified with the score of 8 on the scale, medium adherers with a score of 6 to <8, and low adherers with a score of <6.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	Reason for ITP treatment discontinuation or change from one ITP treatment to another, prior to as well as during the study.	Information will be collected via the patient's medical records.	Data will be collected retrospectively via the medical records for a time period of 12 months prior to Doptelet start as well as prospectively for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	Patient satisfaction with outcome of Doptelet treatment using the Treatment Satisfaction Questionnaire for Medication (TSQM-9).	TSQM-9 is a self-administered generic measure to assess patients' satisfaction with their medication. It consists of nine items distributed across three dimensions: Effectiveness (3 items), Convenience (3 items) and Global satisfaction scale (3 items). Each domain score ranges from 0 to 100, higher score indicating greater satisfaction.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	Physician satisfaction with outcome of Doptelet treatment using a 5 point scale.	The treating physician will evaluate satisfaction with the Doptelet treatment by answering the question: "On a scale of 1-5 with 5 being highly satisfied and 1 being highly dissatisfied, how would you rate your satisfaction with the desired treatment outcome of the Doptelet treatment?"	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	Physician assessment of clinical change of Doptelet treatment using the Clinical Global Impression of Change (CGIC) scale.	The treating physician will evaluate the clinical change of Doptelet treatment by grading the change on a 7-point scale; very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	Change from enrollment in the European Quality of Life - 5 Dimensions (EQ-5D-5L) scale.	The EQ-5D is a standardized generic instrument for use as a measure of health outcome. The EQ-5D consists of 2 parts - the EQ-5D descriptive profile which is mapped into a single index value for health status (utility value) and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	Change from enrollment in the Immune Thrombocytopenic Purpura Patient Assessment Questionnaire (ITP-PAQ).	ITP-PAQ is a disease-specific self-administered tool which was developed and validated to assess health related quality of life (HRQoL) in adult patients with ITP using a 4-week recall period. It consists in 44 items distributed across 10 dimensions: Symptoms (6 items), Bother-Physical Health (3 items), Fatigue/Sleep (4 items), Activity (2 items), Fear (5 items), Psychological Health (5 items), Work (4 items), Social Activity (4 items), Women's Reproductive Health (6 items) and Overall QoL (5 items). Each scale is scored from 0 to 100, with higher scores representing better HRQoL.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	Change from enrollment in the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) questionnaire.	FACIT-Fatigue is a 13-item scale developed to assess specifically quality of life concerns related to fatigue in patients with chronic diseases. The scale was initially developed to assess cancer-related fatigue, however it has been since then used and psychometrically validated in other chronic diseases, including ITP. The instrument includes items such as tiredness, weakness, listlessness, lack of energy, and the impact of these feelings on daily functioning over the past seven days. Each item is scored on a 5-point Likert Scale ranging from "0-Not at all" to "4-Very much".	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	Change from enrollment in Patient Global Impression of Change (PGIC) scale.	PGIC will be used to evaluate patients' perception of changes in the severity of their ITP symptoms on the scale: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	Change from enrollment in Work Productivity and Activity Impairment (WPAI) questionnaire.	WPAI for specific health problem, WPAI:SHP v2.0 questionnaire is a generic and standard instrument developed to measure the effect of specific health problems and symptom severity on work productivity and regular activities during the past seven days. It contains six items which ascertain employment status and quantify absenteeism due to health problems, presenteeism and overall health-related impairment in both paid work and regular activities over the previous 7 days. The WPAI provides quantitative data at the item level compatible with economic modelling.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	Healthcare resource use including; Inpatient and /or outpatient visits since last routine visit.	The following data related to in-patient and/or out-patient visits since last routine visit will be collected: Length of hospitalization; Reason for visit; Surgical procedures; ICU stay, CT scans; Regular blood tests and haemato-chemistry blood tests; Platelet transfusions; Other.	Data will be collected retrospectively via the medical records for a time period of 12 months prior to Doptelet start as well as prospectively for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	Use of concomitant ITP medications throughout the study.	Information will be collected via the patient's medical records.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	Serious adverse events (SAEs)	Information will be collected via reports from the Investigators based on the patient's medical records.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	Adverse events of special interest (AESIs) (e.g., thromboembolic events, significant bleeding (WHO bleeding scale grade = 3)).	Information will be collected via reports from the Investigators based on the patient's medical records.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Secondary	AEs leading to Doptelet discontinuation.	Information will be collected via reports from the Investigators based on the patient's medical records.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.